DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here

    Age-Related Macular Degeneration: Disease Landscape & Forecast

    Following the introduction of the anti-vascular endothelial growth factor (VEGF) therapies over a decade ago, the wet age-related macular degeneration (AMD) market has been dominated by three therapies—Roche/Genentech/Novartis’s Lucentis, approved for wet AMD, Roche/Genentech/Chugai’s Avastin, approved for cancer but commonly compounded and used off-label for wet AMD, and, most recently, Regeneron/Bayer HealthCare/Santen’s Eylea, which has experienced strong and continued uptake at the expense of the other drugs within this class.

    Although the majority of AMD patients are diagnosed with the dry form of AMD, management of this disease type is limited to minimally effective vitamin formulations because no prescription pharmacotherapies are approved for this large and underserved subpopulation. However, the pipeline features a growing number of novel agents targeting the advanced form of dry AMD (i.e., geographic atrophy [GA]), as well as therapies for wet AMD.

    This report will answer the following key questions:

    • Do KOLs perceive any differences between the mainstays Avastin, Eylea, and Lucentis? How is their use expected to change, if at all, over the next ten years?
    • Biosimilar versions of Eylea and Lucentis are forecast to launch within the next ten years. What is the likely impact of these therapies on current and emerging VEGF inhibitors?
    • Therapies with longer dosing intervals than offered by current therapies represents a substantial unmet need in wet AMD. To what extent are the emerging VEGF inhibitors Novartis’s RTH-258 and Allergan’s abicipar pegol expected to capitalize on this unmet need?

    About Decision Resources Group's Disease Landscape & Forecast Solution

    Found in the Insights Platform, our Disease Landscape & Forecast solution offers disease-specific analysis and expert-level forecast of the commercial outlook for drugs currently on the market and those in research and development. Learn more about how you can fully understand a disease, including the science, the patient population, and the current and future therapeutic landscape through detailed, accurate, reliable, and timely analyses.